Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema

BACKGROUND: ASP8232 is a potent and specific small molecule vascular adhesion protein-1 (VAP-1) inhibitor. This study evaluated the effect of ASP8232 on excess retinal thickness when given alone or in combination with ranibizumab in patients with center-involved diabetic macular edema (CI-DME). METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Quan Dong, Sepah, Yasir J., Berger, Brian, Brown, David, Do, Diana V., Garcia-Hernandez, Alberto, Patel, Sunil, Rahhal, Firas M., Shildkrot, Yevgeniy, Renfurm, Ronny W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6670150/
https://www.ncbi.nlm.nih.gov/pubmed/31388454
http://dx.doi.org/10.1186/s40942-019-0178-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6670150/
https://www.ncbi.nlm.nih.gov/pubmed/31388454
http://dx.doi.org/10.1186/s40942-019-0178-7

Ejemplares similares